MM

Melinda McGrath

Australian Clinical Labs Limited | Chief Executive Officer, Executive Director
Ms McGrath has more than 30 years' experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Melinda was Chief Executive Officer of QML Pathology (part of Healius/ Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super.

Company and Roles

Company
Title
Tenure
Since
ACL
Australian Clinical Labs Limited
  • Chief Executive Officer
  • Executive Director
5yrs, 5mthDec 2020

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ACL
Australian Clinical Labs Limited
30/06/252,173,867749,464N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ACL
Australian Clinical Labs Limited
26/08/24
Expiry
247,252$2.810$694,778As advised by the company
ACL
Australian Clinical Labs Limited
20/12/23
Issued
395,490$2.280$901,717Issue of securities
ACL
Australian Clinical Labs Limited
13/03/23
Issued
238,092$3.780$899,987Issue of securities
ACL
Australian Clinical Labs Limited
15/09/22
Issued
65,658$4.270$280,359Dividend Reinvestment Plan (DRP)
ACL
Australian Clinical Labs Limited
21/04/22
Issued
15,841$5.060$80,155Dividend Reinvestment Plan (DRP)